Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $8.52, but opened at $9.09. Pharming Group shares last traded at $9.24, with a volume of 1,705 shares changing hands.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on PHAR. Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th. Finally, Oppenheimer dropped their target price on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th.
Check Out Our Latest Research Report on PHAR
Pharming Group Stock Performance
The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $9.34 and a two-hundred day moving average price of $8.49. The firm has a market cap of $608.87 million, a PE ratio of -34.42 and a beta of -0.10.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
